Manuka honey activates the aryl hydrocarbon receptor: Implications for skin inflammation

Manuka honey (MH) is a complex nutritional material with antimicrobial, antioxidant and anti-inflammatory activity. We have previously shown that MH down regulates IL-4-induced CCL26 expression in immortalized keratinocytes. As MH contains potential ligands of the Aryl Hydrocarbon Receptor (AHR), a...

Full description

Saved in:
Bibliographic Details
Main Authors: Abdullah A. Alangari (Author), Matin D. Ashoori (Author), Wisam Alwan (Author), Hannah R. Dawe (Author), Brigitta Stockinger (Author), Jonathan N. Barker (Author), Emma Wincent (Author), Paola Di Meglio (Author)
Format: Book
Published: Elsevier, 2023-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_c20ee10894c9425a895b1a18e20ffc4a
042 |a dc 
100 1 0 |a Abdullah A. Alangari  |e author 
700 1 0 |a Matin D. Ashoori  |e author 
700 1 0 |a Wisam Alwan  |e author 
700 1 0 |a Hannah R. Dawe  |e author 
700 1 0 |a Brigitta Stockinger  |e author 
700 1 0 |a Jonathan N. Barker  |e author 
700 1 0 |a Emma Wincent  |e author 
700 1 0 |a Paola Di Meglio  |e author 
245 0 0 |a Manuka honey activates the aryl hydrocarbon receptor: Implications for skin inflammation 
260 |b Elsevier,   |c 2023-08-01T00:00:00Z. 
500 |a 1096-1186 
500 |a 10.1016/j.phrs.2023.106848 
520 |a Manuka honey (MH) is a complex nutritional material with antimicrobial, antioxidant and anti-inflammatory activity. We have previously shown that MH down regulates IL-4-induced CCL26 expression in immortalized keratinocytes. As MH contains potential ligands of the Aryl Hydrocarbon Receptor (AHR), a key regulator of skin homeostasis, we hypothesize that this effect is mediated via AHR activation. Here, we treated HaCaT cell lines, either stable transfected with an empty vector (EV-HaCaT) or in which AHR had been stable silenced (AHR-silenced HaCaT); or primary normal human epithelial keratinocytes (NHEK) with 2% MH for 24 h. This induced a 15.4-fold upregulation of CYP1A1 in EV-HaCaTs, which was significantly reduced in AHR-silenced cells. Pre-treatment with the AHR antagonist CH223191 completely abrogated this effect. Similar findings were observed in NHEK. In vivo treatment of the Cyp1a1Cre x R26ReYFP reporter mice strain's skin with pure MH significantly induced CYP1A1 expression compared with Vaseline. Treatment of HaCaT with 2% MH significantly decreased baseline CYP1 enzymatic activity at 3 and 6 h but increased it after 12 h, suggesting that MH may activate the AHR both through direct and indirect means. Importantly, MH downregulation of IL-4-induced CCL26 mRNA and protein was abrogated in AHR-silenced HaCaTs and by pre-treatment with CH223191. Finally, MH significantly upregulated FLG expression in NHEK in an AHR-dependent manner. In conclusion, MH activates AHR, both in vitro and in vivo, thereby providing a mechanism of its IL4-induced CCL26 downregulation and upregulation of FLG expression. These results have potential clinical implications for atopic diseases and beyond. 
546 |a EN 
690 |a Aryl hydrocarbon receptor (AHR) 
690 |a CCL26 
690 |a Filaggrin 
690 |a IL-4 
690 |a Manuka honey 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Pharmacological Research, Vol 194, Iss , Pp 106848- (2023) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S1043661823002049 
787 0 |n https://doaj.org/toc/1096-1186 
856 4 1 |u https://doaj.org/article/c20ee10894c9425a895b1a18e20ffc4a  |z Connect to this object online.